<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liquid ventilation: An investigational technique</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liquid ventilation: An investigational technique</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Liquid ventilation: An investigational technique</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Manaker, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Polly E Parsons, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Liquid ventilation (LV) is an investigational technique of mechanical ventilation in which the lungs are insufflated with an oxygenated perfluorochemical liquid rather than an oxygen-containing gas mixture. Despite its theoretical advantages, efficacy studies have been disappointing and the optimal clinical use of LV has yet to be defined [<a href="#rid1">1</a>].</p><p>The technique and potential applications of LV will be reviewed here. Conventional and alternative modes of gas-phase mechanical ventilation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit"</a> and  <a class="medical medical_review" href="/z/d/html/1651.html" rel="external">"Modes of mechanical ventilation"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PROPERTIES</span><span class="headingEndMark"> — </span>The ideal fluid for LV is nontoxic, has a low surface tension, is capable of dissolving large amounts of oxygen and carbon dioxide, has minimal systemic absorption, and is chemically stable [<a href="#rid2">2</a>]. Following work with hyperbaric <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> ventilation [<a href="#rid3">3</a>], researchers demonstrated that perfluorochemicals (PFCs) had many of these properties and could be used as a medium for liquid breathing in rodents [<a href="#rid4">4</a>].</p><p>The use of perfluorochemicals, rather than nitrogen, as the inert carrier of oxygen and carbon dioxide offers a number of theoretical advantages for the treatment of acute lung injury, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing surface tension by maintaining a fluid interface with alveoli</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opening of collapsed alveoli by hydraulic pressure with a lower risk of barotrauma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing a reservoir in which oxygen and carbon dioxide can be exchanged with pulmonary capillary blood</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functioning as a high efficiency heat exchanger</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mobilizing alveolar and airway debris and exudates</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Physical properties</span><span class="headingEndMark"> — </span>PFCs are organic compounds in which some carbon-bound hydrogen atoms have been replaced with fluorine atoms [<a href="#rid5">5</a>]. Perflubron (LiquiVent), the only medical grade PFC available for use in human LV trials, consists of a long, linear-fluorinated hydrocarbon chain. Perflubron contains one bromide atom, making it radiopaque [<a href="#rid5">5</a>].</p><p>Hundreds of different PFC fluids with unique biomedical properties exist. The structure of several examples of these compounds is shown in the figure  (<a class="graphic graphic_figure graphicRef80558" href="/z/d/graphic/80558.html" rel="external">figure 1</a>). The table compares the physical properties of air, water, and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> with three PFCs that have been studied for LV  (<a class="graphic graphic_table graphicRef52864" href="/z/d/graphic/52864.html" rel="external">table 1</a>) [<a href="#rid6">6,7</a>].</p><p>PFC fluids are clear, colorless, odorless, and inert. Oxygen, carbon dioxide, and other gases are highly soluble in these fluids; they can dissolve over 15 times the amount of oxygen per given volume as plasma [<a href="#rid8">8</a>]. PFCs are poor solvents for most other biological compounds.</p><p>PFCs are stable, insoluble in water, can be stored indefinitely at room temperature, and can be autoclaved [<a href="#rid8">8,9</a>]. In contrast to <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, PFCs do not wash out surfactant [<a href="#rid1">1</a>]. Almost all PFC fluids have low surface tension and are nonbiotransformable. However, PFCs have a high viscosity, which makes their flow characteristics problematic under certain circumstances.</p><p class="headingAnchor" id="H4"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Very small amounts of PFCs diffuse into the pulmonary capillary blood and dissolve in blood lipids [<a href="#rid10">10</a>]. The rate of uptake in the blood depends upon the PFC vapor pressure, permeability coefficients of the blood vessels, solubility of the particular PFC used, and the degree of ventilation/perfusion matching.</p><p>Absorbed PFCs are scavenged by macrophages. The main route of PFC elimination is through the lungs via volatilization [<a href="#rid11">11,12</a>]. To a smaller degree, the chemicals are eliminated through the skin by transpiration. Perflubron blood concentrations are low but measurable, and persist for at least eight days following administration of the last dose of perflubron [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H5"><span class="h1">TECHNIQUES</span><span class="headingEndMark"> — </span>Two methods of perfluorochemical (PFC)-based LV have been used: total (tidal) LV and partial LV.</p><p class="headingAnchor" id="H6"><span class="h2">Total liquid ventilation</span><span class="headingEndMark"> — </span>In total LV (TLV), the entire lung is filled with an oxygenated PFC liquid, and a liquid tidal volume of PFC is actively pumped into and out of the lungs. A specialized apparatus is required to deliver and remove the relatively dense, viscous PFC tidal volumes, and to extracorporeally oxygenate and remove carbon dioxide from the liquid [<a href="#rid2">2,9,14</a>].</p><p>TLV is initiated by insufflating the desired volume of pre-oxygenated PFC liquid (functional residual capacity plus tidal volume) into the lungs using a gravity-assisted device or more specialized equipment [<a href="#rid6">6,9</a>]. Optimum ventilation and oxygenation depend upon adequate minute ventilation coupled with sufficient time for diffusion of respiratory gases to and from the PFC liquid [<a href="#rid6">6,9</a>]. During the maintenance phase of TLV, a low respiratory rate (eg, four to six breaths per minute) is set with an inspiratory-to-expiratory (I:E) ratio of 1:2 to 1:3 [<a href="#rid15">15</a>]. At these respiratory rates and timing ratios, PFC fluid dwells in the lung long enough for diffusion of respiratory gases to occur, thus effecting pulmonary gas exchange. Tidal volumes and peak inspiratory and positive end expiratory pressures (PEEP) are adjusted based upon pulmonary mechanics and blood gases in the same manner as when gas ventilation is employed. (See  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a> and  <a class="medical medical_review" href="/z/d/html/1642.html" rel="external">"Positive end-expiratory pressure (PEEP)"</a>.)</p><p>TLV is weaned when sufficient clinical improvement has occurred such that gas ventilation will be adequate to support the patient; specific weaning parameters and techniques have not been fully evaluated. The return to gas ventilation is accomplished by a transition through a period of partial LV (see <a class="local">'Partial liquid ventilation'</a> below). PFC liquid is removed at the end of the expiratory phase, leaving a volume of PFC fluid equivalent to the functional residual capacity of the lung. Gas ventilation is begun, and the PFC fluid is not replaced or augmented as it is evaporated; elimination from the lung by evaporation generally requires one to seven days [<a href="#rid6">6,16</a>]. In some cases, small amounts of PFC are radiographically apparent in the lungs for several weeks or longer without apparent ill effects [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Partial liquid ventilation</span><span class="headingEndMark"> — </span>In partial LV (PLV), the lungs are slowly filled with a volume of PFC equivalent or close to the FRC during gas ventilation. The PFC within the lungs is oxygenated and carbon dioxide is removed by means of gas breaths cycling in the lungs by a conventional gas ventilator [<a href="#rid6">6</a>].</p><p>PLV is initiated by insufflating PFC liquid (approximately 20 to 30 mL/kg) into the lungs using an intravenous syringe pump or by slowly pushing the fluid in over a 15-minute to one-hour period. The functional residual capacity is reached when a meniscus of PFC is present within the endotracheal tube at end-expiration [<a href="#rid17">17</a>].</p><p>As the fluid evaporates out of the lungs, it is intermittently and gradually replaced with additional PFC at approximately 2 to 8 mL/kg/hour to maintain a total liquid volume of functional residual capacity [<a href="#rid6">6,9</a>]. Typically, but not exclusively, pressure-controlled ventilation with the addition of PEEP is used to deliver gas ventilation, and fraction of inspired oxygen (FiO<sub>2</sub>) and PEEP are adjusted based upon pulmonary mechanics and blood gases [<a href="#rid18">18</a>].</p><p>Airway suctioning is still required with PLV [<a href="#rid1">1</a>]. PLV is discontinued by ceasing to replace the PFC that is lost through evaporation. Most of the intrapulmonary PFC evaporates in the next one to seven days, allowing a transition to gas ventilation [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Comparison</span><span class="headingEndMark"> — </span>TLV allows the lavage and removal of lung secretions, meconium, or alveolar edema from the lower airways to a greater extent than PLV. In addition, the distribution of PFC within the lungs may be more uniform during TLV than PLV. However, TLV requires a specialized delivery apparatus, and increased airway resistance can make the tidal delivery of viscous PFCs difficult.</p><p>PLV provides some of the same benefits as TLV by maintaining a liquid interface in the alveoli, but does not require specialized equipment. The technique may also be possible in some patients in whom elevated airway resistance precludes the use of TLV. Periodic repositioning of the patient is required with both modes to ensure optimal distribution of PFC fluid within the lungs but is more important in PLV to maintain a liquid interface in as many alveoli as possible.</p><p class="headingAnchor" id="H9"><span class="h1">PHYSIOLOGIC OUTCOMES</span><span class="headingEndMark"> — </span>LV offers a number of theoretical advantages over conventional gas ventilation, including better gas exchange and functional lung recovery by any of several mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Alveolar recruitment – Filling of alveoli with liquid rather than gas eliminates air-liquid interfaces and greatly reduces surface tension forces. Collapsed alveoli may also be recruited and stabilized by the hydraulic forces provided during LV. Alveolar expansion and stability is thus facilitated at much lower airway pressures, reducing the risk of barotrauma [<a href="#rid14">14,19</a>]. As more alveoli are filled with oxygen-rich perfluorochemical (PFC), the effective diffusing surface of the lung increases and is reflected by improvement in arterial oxygenation and compliance [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Better V/Q matching – PFC fluids are denser than water and therefore deposit in dependent regions of the lungs. They improve ventilation/perfusion matching by facilitating gas exchange in lung units that were previously perfused but unventilated. The weight of PFCs within dependent lung zones also may redistribute pulmonary blood flow to nondependent zones that were previously ventilated but unperfused [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lavage – LV facilitates the removal of exudative material from the lung but does not interfere substantially with the production or function of surfactant [<a href="#rid1">1,23</a>]. During TLV, the cyclical removal and replacement of PFC liquid may cleanse the lungs while maintaining gas exchange [<a href="#rid24">24</a>]. During PLV, exudative material in the peripheral airways and alveoli is lavaged to the central airways for removal via suctioning [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-inflammatory effects – Some studies suggest reduced neutrophil and alveolar macrophage responses exist in the presence of PFCs, including attenuation of neutrophil adhesion, activation, and migration [<a href="#rid25">25-31</a>]. Preclinical studies suggest perfluorocarbons inhibit inflammatory cytokine expression and inflammatory mediator signaling pathways [<a href="#rid32">32</a>] and attenuate ICAM-1 expression in injured alveolar cells [<a href="#rid33">33</a>]. The removal of inflammatory cells and their mediators from the alveolar spaces may also provide benefit [<a href="#rid26">26,34</a>]. Finally, filling of the alveolus with PFCs may provide a mechanical barrier to intra-alveolar exudation and leukocyte and/or red blood cell translocation, with potential beneficial effects in reducing the intensity of inflammation and secondary lung injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Temperature regulation – PFC liquids have a higher heat capacity than conventional gas mixtures. This allows the lung and pulmonary circulation to act as an internal heat exchanger [<a href="#rid35">35</a>]. PFC liquids can be used to warm the lungs and increase core body temperature or cool the lungs and decrease core body temperature, as required by clinical circumstances [<a href="#rid6">6,36</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">POTENTIAL INDICATIONS</span><span class="headingEndMark"> — </span>The unique properties of perfluorochemical (PFC)-based LV make the technique potentially useful in a variety of neonatal and adult application. These applications remain investigational.</p><p class="headingAnchor" id="H11"><span class="h2">Neonatal applications</span></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory distress syndrome – Exogenous surfactant therapy in infants with neonatal respiratory distress syndrome (hyaline membrane disease) is limited by unequal delivery and distribution within the injured or premature lung [<a href="#rid37">37</a>]. LV may facilitate more uniform endogenous surfactant distribution, and may be of use in surfactant-unresponsive cases. In either event, LV can reduce surface tension, thereby reducing inflation pressure and barotrauma, and may stimulate surfactant synthesis [<a href="#rid23">23,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meconium aspiration – Lavage associated with total LV (TLV) and partial LV (PLV) may remove meconium from the airways more effectively than conventional measures [<a href="#rid39">39-41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent pulmonary hypertension of the newborn – LV provides uniform delivery of oxygen to the distal regions of the lungs, potentially improving ventilation/perfusion matching and facilitating pulmonary vasodilation [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital diaphragmatic hernia – PLV may improve gas exchange more effectively than conventional gas ventilation in newborns with severe congenital diaphragmatic hernia and may provide mechanical stimuli (eg, pressure transduction) that favor neonatal lung growth [<a href="#rid42">42-46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Temperature control – The heat exchange characteristic of PFCs may help maintain normothermia in premature infants with less reliance upon radiant warmers, which increase insensible water loss [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung protection during cardiopulmonary bypass – Full, functional residual capacity dosing prior to bypass may reduce cardiopulmonary bypass-associated lung injury [<a href="#rid47">47</a>]. Anti-inflammatory effects, alveolar distention, oxygen-carrying capacity, and surfactant-like properties may protect the lung before and during cardiopulmonary bypass.</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Adult applications</span></p><p class="bulletIndent1"><span class="glyph">●</span>Acute respiratory distress syndrome – LV potentially can improve gas exchange in ARDS by virtue of recruiting the atelectatic, consolidated, dependent regions of the lungs that contribute to the physiologic shunt observed during gas ventilation. Pulmonary blood flow is also redistributed to less severely injured and/or atelectatic regions of the lungs, thus improving ventilation/perfusion matching [<a href="#rid14">14,21,22,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia – Lavage associated with TLV and PLV removes infectious and inflammatory debris from the airways [<a href="#rid40">40,41</a>]. Antibiotics such as <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> can be suspended within the PFC vehicle to potentially facilitate treatment or prevention of pneumonia [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer therapy – LV may augment the antineoplastic effects of radiotherapy and chemotherapy in the lung by inducing localized hyperthermia or hyperoxia of the lung surface. Concentrated, topical chemotherapeutic agents can also be delivered [<a href="#rid5">5,8,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug delivery – Mechanical abnormalities of the lung, intrapulmonary shunting, ventilation/perfusion mismatching, and elevated surface tension impede effective delivery of systemic and intratracheal drugs to the lungs during conventional gas ventilation [<a href="#rid51">51</a>]. Antibacterial perfluorocarbon ventilation (APV) may improve antibiotic delivery to the lungs [<a href="#rid52">52</a>]. Data from preliminary animal studies suggest that pulmonary uptake of antibiotics and <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> and the efficacy of vasoactive drugs are better following intratracheal administration during LV than when administered intravenously [<a href="#rid51">51,53-55</a>]. In an animal model, administration of liquid perfluorocarbon containing emulsified <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> resulted in a higher local concentration and lower systemic concentration than conventional aerosolized tobramycin delivery [<a href="#rid56">56</a>]. New pulmonary drug delivery technologies such as lipid-based hollow-porous microparticles combined with perfluorocarbons are under investigation [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Donor lung preservation – Because perfluorochemicals have both direct anti-inflammatory and alveolar stabilizing effects, these agents have been proposed as potential useful tools for organ preservation prior to lung transplantation. Preliminary investigations have suggested that LV results in decreased alveolar destruction when compared to standard (gas) ventilation [<a href="#rid58">58,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapeutic hypothermia – Preclinical studies of temperature management with perfluorocarbons delivered via partial or total LV and lung lavage suggest several potential clinical applications, including end-organ preservation post cardiac arrest [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">CLINICAL OUTCOME</span><span class="headingEndMark"> — </span>Clinical human data are limited and do not support routine use of total or partial LV at this time [<a href="#rid16">16,39,40,42,61-69</a>]. Most studies have evaluated the ability of LV to improve gas exchange and pulmonary function in animal models.</p><p>Trials that have compared PLV versus conventional mechanical ventilation (CMV) in adults with acute respiratory distress syndrome (ARDS) are listed below:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2013 meta-analysis review of two randomized controlled trials that compared PLV with CMV in the treatment of acute lung injury with or without acute respiratory distress syndrome in adults evaluated two trials with a total of 401 participants [<a href="#rid70">70</a>]. There were nonsignificant trends towards a higher 28-day mortality and fewer ventilator-free days with PLV. Pooled estimates of adverse effects suggested an increased risk for bradycardia (p = 0.005) and increased though nonsignificant risks for hypoxemia, hypotension, barotrauma, and cardiac collapse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one trial, 311 patients were randomly assigned to receive CMV, low dose PLV (lungs filled to the carina in the supine position), or high dose PLV (lungs filled to 5 cm caudal to the incisors in the supine position) [<a href="#rid68">68</a>]. There was no difference in mortality among the groups; however, patients who received PLV had fewer ventilator-free days and more adverse events.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial of 90 patients, those who received PLV were less likely to have progressive deterioration of gas exchange; however, there was no difference in the number of ventilator-free days, the incidence of mortality, or any respiratory parameter [<a href="#rid66">66</a>].</p><p></p><p>In a small trial that included 13 neonates with congenital diaphragmatic hernias on extracorporeal life support (ECLS), patients who received PLV had a nonstatistically significant improvement in survival and time on ECLS compared to patients who received CMV [<a href="#rid67">67</a>]. However, ventilator-free days were greater in the CMV group.</p><p>There are no published controlled studies of PLV versus other forms of ventilator management in the treatment of acute lung injury or ARDS in children (28 days to 18 years of age) [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H14"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The complete range of toxicity due to perfluorochemicals (PFCs) is not known. Early studies using total LV (TLV) reported an increase in pulmonary vascular resistance with a decrease in cardiac index of approximately 40 percent, which resulted in lactic acidosis [<a href="#rid1">1</a>]. This probably was a consequence of lung overexpansion, which may decrease cardiac output and arterial blood pressure. In contrast, adverse direct hemodynamic effects appear uncommon during partial LV (PLV).</p><p>Other adverse effects observed during PFC LV include mucous plug formation, pneumothoraces, and bleeding complications, but it is unclear to what degree these relate to LV rather than the underlying disease [<a href="#rid39">39,40</a>].</p><p>The long-term adverse effects of breathing PFCs appear to be negligible but remain under investigation [<a href="#rid9">9</a>]. Perflubron may persist in extrapulmonary tissues for years following LV. Two case reports note the continued presence of perflubron in the mediastinum, the retroperitoneum, and the pleural space for 9 and 12 years, respectively [<a href="#rid71">71,72</a>]. Such case reports describe the presence of pseudocalcified extraparenchymal PFC nodules 9 to 15 years following LV [<a href="#rid71">71-73</a>]. Alveolar rupture may also allow PFC to leak into underaerated spaces.</p><p>LV potentially can complicate some of the supportive and general care that ventilated patients receive in the intensive care unit:</p><p class="bulletIndent1"><span class="glyph">●</span>PFC fluid is almost twice as dense as <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, and patient weights should not be followed as the sole index of fluid balance when LV is used [<a href="#rid6">6,7</a>]. A dry weight should be obtained before the start of LV, and patients should be weighed again immediately after the lungs are filled with PFC fluid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PFCs are radiopaque and will eliminate much of the diagnostic utility of chest radiography. All lung tissue will appear opacified during TLV; during PLV, an anterior-posterior supine film may appear uniformly radiopaque, but a lateral view of the chest will reveal the distribution of PFC primarily within the dependent portions of the lung. A chest radiograph should be obtained prior to and within an hour of filling the lung with PFC fluid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heart sounds are more distinct during TLV than PLV. Breath sounds during PLV are notable for the presence of fine rales and coarse rhonchi. No audible breath sounds are present during TLV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impact of LV upon the development of nosocomial pneumonia is uncertain. Lavaging the lung of infectious exudate during LV may be beneficial, but this may be offset by the loss of diagnostic information usually provided by chest radiography [<a href="#rid6">6,24,39</a>]. PFCs are thought to be inert.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of LV is unpleasant for the patient, and therefore deep sedation and paralysis are necessary [<a href="#rid6">6,14</a>]. The principles of using sedative and paralytic agents are similar to those applied when conventional gas ventilation is employed. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a> and  <a class="medical medical_review" href="/z/d/html/1590.html" rel="external">"Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">FUTURE</span><span class="headingEndMark"> — </span>The future of LV is unclear. There are no current human LV trials, though basic science research using <em>in vitro</em> and animal lung models continues.</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Liquid ventilation (LV) is an investigational technique of mechanical ventilation in which the lungs are insufflated with oxygenated perfluorochemical (PFC) liquid rather than gas. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PFC liquids are stable and nontoxic, with minimal systemic absorption. They dissolve large amounts of oxygen and carbon dioxide; thus, they are ideal for gas exchange. (See <a class="local">'Properties'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two techniques of PFC-based LV have been used, total (tidal) LV and partial LV. (See <a class="local">'Techniques'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Theoretical advantages of LV over conventional gas ventilation include recruitment and stabilization of alveoli, improvement in V/Q matching, removal of exudative material from the lung, direct anti-inflammatory effects, and temperature regulation. (See <a class="local">'Physiologic outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In theory, LV may be of benefit for numerous neonatal and adult diseases. Clinical trials, however, have shown little improvement in important clinical outcomes. As a result, LV cannot be recommended in routine clinical care. (See <a class="local">'Potential indications'</a> above and <a class="local">'Clinical Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse effects observed during LV include mucous plug formation, pneumothoraces, and bleeding complications, although it is unclear whether these were due to LV or the underlying disease. Long-term retention of PFC residue in nonparenchymal tissues has been reported. (See <a class="local">'Adverse Effects'</a> above.)</p><p></p><p class="headingAnchor" id="H2515791051"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Karen J Tietze, PharmD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Degraeuwe PL, Vos GD, Blanco CE. Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit. Int J Artif Organs 1995; 18:674.</a></li><li><a class="nounderline abstract_t">Norris MK, Fuhrman BP, Leach CL. Liquid ventilation: it's not science fiction anymore. AACN Clin Issues Crit Care Nurs 1994; 5:246.</a></li><li><a class="nounderline abstract_t">KYLSTRA JA, TISSING MO, van der MAEN . Of mice as fish. Trans Am Soc Artif Intern Organs 1962; 8:378.</a></li><li><a class="nounderline abstract_t">Clark LC Jr, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152:1755.</a></li><li><a class="nounderline abstract_t">Riess JG. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomater Artif Cells Immobilization Biotechnol 1992; 20:183.</a></li><li><a class="nounderline abstract_t">Cox CA, Wolfson MR, Shaffer TH. Liquid ventilation: a comprehensive overview. Neonatal Netw 1996; 15:31.</a></li><li><a class="nounderline abstract_t">Shaffer TH. A brief review: liquid ventilation. Undersea Biomed Res 1987; 14:169.</a></li><li><a class="nounderline abstract_t">Shaffer TH, Wolfson MR, Clark LC Jr. Liquid ventilation. Pediatr Pulmonol 1992; 14:102.</a></li><li><a class="nounderline abstract_t">Greenspan JS. Physiology and clinical role of liquid ventilation therapy. J Perinatol 1996; 16:S47.</a></li><li><a class="nounderline abstract_t">Wolfson MR, Kechner NE, Rubenstein D, et al. Perfluorochemical (PFC) uptake and biodistribution following liquid assisted ventilation in the immature lamb. Pediatr Res 1994; 35:A246.</a></li><li><a class="nounderline abstract_t">Gauthier SP, Wolfson MR, Deoras KS, Shaffer TH. Structure-function of airway generations 0 to 4 in the preterm lamb. Pediatr Res 1992; 31:157.</a></li><li><a class="nounderline abstract_t">Wolfson MR, Clark LC, Hoffmann RE, et al. Liquid ventilation of neonates: Uptake, distribution, and elimination of the liquid. Pediatr Res 1990; 27:37A.</a></li><li><a class="nounderline abstract_t">Reickert C, Pranikoff T, Overbeck M, et al. The pulmonary and systemic distribution and elimination of perflubron from adult patients treated with partial liquid ventilation. Chest 2001; 119:515.</a></li><li><a class="nounderline abstract_t">Dirkes S. Liquid ventilation: new frontiers in the treatment of ARDS. Crit Care Nurse 1996; 16:53.</a></li><li><a class="nounderline abstract_t">Koen PA, Wolfson MR, Shaffer TH. Fluorocarbon ventilation: maximal expiratory flows and CO2 elimination. Pediatr Res 1988; 24:291.</a></li><li><a class="nounderline abstract_t">Leach CL, Greenspan JS, Rubenstein SD, et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group. N Engl J Med 1996; 335:761.</a></li><li><a class="nounderline abstract_t">Hirschl RB. Advances in the management of respiratory failure. Liquid ventilation in the setting of respiratory failure. ASAIO J 1996; 42:209.</a></li><li><a class="nounderline abstract_t">Kirmse M, Fujino Y, Hess D, Kacmarek RM. Positive end-expiratory pressure improves gas exchange and pulmonary mechanics during partial liquid ventilation. Am J Respir Crit Care Med 1998; 158:1550.</a></li><li><a class="nounderline abstract_t">Tütüncü AS, Faithfull NS, Lachmann B. Intratracheal perfluorocarbon administration combined with mechanical ventilation in experimental respiratory distress syndrome: dose-dependent improvement of gas exchange. Crit Care Med 1993; 21:962.</a></li><li><a class="nounderline abstract_t">Fuhrman BP, Paczan PR, DeFrancisis M. Perfluorocarbon-associated gas exchange. Crit Care Med 1991; 19:712.</a></li><li><a class="nounderline abstract_t">Berry D, Ikegami M, Jobe A. Respiratory distress and surfactant inhibition following vagotomy in rabbits. J Appl Physiol (1985) 1986; 61:1741.</a></li><li><a class="nounderline abstract_t">Lowe CA, Shaffer TH. Pulmonary vascular resistance in the fluorocarbon-filled lung. J Appl Physiol (1985) 1986; 60:154.</a></li><li><a class="nounderline abstract_t">Steinhorn DM, Leach CL, Fuhrman BP, Holm BA. Partial liquid ventilation enhances surfactant phospholipid production. Crit Care Med 1996; 24:1252.</a></li><li><a class="nounderline abstract_t">Richman PS, Wolfson MR, Shaffer TH. Lung lavage with oxygenated perfluorochemical liquid in acute lung injury. Crit Care Med 1993; 21:768.</a></li><li><a class="nounderline abstract_t">Angelova M, Nakazawa K, Yokoyama K, Makita K. Effects of partial liquid ventilation on lipopolysaccharide-induced inflammatory responses in rats. Resuscitation 2004; 62:89.</a></li><li><a class="nounderline abstract_t">Smith TM, Steinhorn DM, Thusu K, et al. A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages. Crit Care Med 1995; 23:1533.</a></li><li><a class="nounderline abstract_t">Virmani R, Fink LM, Gunter K, English D. Effect of perfluorochemical blood substitutes on human neutrophil function. Transfusion 1984; 24:343.</a></li><li><a class="nounderline abstract_t">Varani J, Hirschl RB, Dame M, Johnson K. Perfluorocarbon protects lung epithelial cells from neutrophil-mediated injury in an in vitro model of liquid ventilation therapy. Shock 1996; 6:339.</a></li><li><a class="nounderline abstract_t">Koch T, Ragaller M, Haufe D, et al. Perfluorohexane attenuates proinflammatory and procoagulatory response of activated monocytes and alveolar macrophages. Anesthesiology 2001; 94:101.</a></li><li><a class="nounderline abstract_t">Nakstad B, Wolfson MR, Shaffer TH, et al. Perfluorochemical liquids modulate cell-mediated inflammatory responses. Crit Care Med 2001; 29:1731.</a></li><li><a class="nounderline abstract_t">Woods CM, Neslund G, Kornbrust E, Flaim SF. Perflubron attenuates neutrophil adhesion to activated endothelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 2000; 278:L1008.</a></li><li><a class="nounderline abstract_t">Zhang Z, Liang Z, Li H, et al. Perfluorocarbon reduces cell damage from blast injury by inhibiting signal paths of NF-κB, MAPK and Bcl-2/Bax signaling pathway in A549 cells. PLoS One 2017; 12:e0173884.</a></li><li><a class="nounderline abstract_t">Cao L, Li CS, Chang Y, et al. The effects of perfluorocarbon on ICAM-1 expression in LPS-induced A549 cells and the potential mechanism. Mol Med Rep 2016; 13:3700.</a></li><li><a class="nounderline abstract_t">Kelly KP. Partial liquid ventilation--turning back a PAGE on evolution. Br J Anaesth 1997; 78:1.</a></li><li><a class="nounderline abstract_t">Shaffer TH, Forman DL, Wolfson MR. Physiological effects of ventilation with liquid fluorocarbon at controlled temperatures. Undersea Biomed Res 1984; 11:287.</a></li><li><a class="nounderline abstract_t">Forman DL, Bhutani VK, Tran N, Shaffer TH. A new approach to induced hypothermia. J Surg Res 1986; 40:36.</a></li><li><a class="nounderline abstract_t">Antunes MJ, Greenspan JS, Zukowsky K. Advanced ventilation in the neonate. Nurs Clin North Am 1996; 31:405.</a></li><li><a class="nounderline abstract_t">Leach CL, Holm BA, Morin FC, et al. Partial liquid ventilation with LiquiVent' increases endogenous surfactant production in premature lambs with respiratory distress syndrome (RDS). Pediatr Res 1994; 35:220A.</a></li><li><a class="nounderline abstract_t">Hirschl RB, Pranikoff T, Wise C, et al. Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA 1996; 275:383.</a></li><li><a class="nounderline abstract_t">Hirschl RB, Pranikoff T, Gauger P, et al. Liquid ventilation in adults, children, and full-term neonates. Lancet 1995; 346:1201.</a></li><li><a class="nounderline abstract_t">Shaffer TH, Lowe CA, Bhutani VK, Douglas PR. Liquid ventilation: effects on pulmonary function in distressed meconium-stained lambs. Pediatr Res 1984; 18:47.</a></li><li><a class="nounderline abstract_t">Pranikoff T, Gauger PG, Hirschl RB. Partial liquid ventilation in newborn patients with congenital diaphragmatic hernia. J Pediatr Surg 1996; 31:613.</a></li><li><a class="nounderline abstract_t">Wilcox DT, Glick PL, Karamanoukian HL, et al. Partial liquid ventilation and nitric oxide in congenital diaphragmatic hernia. J Pediatr Surg 1997; 32:1211.</a></li><li><a class="nounderline abstract_t">Major D, Cadenas M, Cloutier R, et al. Combined gas ventilation and perfluorochemical tracheal instillation as an alternative treatment for lethal congenital diaphragmatic hernia in lambs. J Pediatr Surg 1995; 30:1178.</a></li><li><a class="nounderline abstract_t">Wilcox DT, Glick PL, Karamanoukian HL, et al. Perfluorocarbon-associated gas exchange improves pulmonary mechanics, oxygenation, ventilation, and allows nitric oxide delivery in the hypoplastic lung congenital diaphragmatic hernia lamb model. Crit Care Med 1995; 23:1858.</a></li><li><a class="nounderline abstract_t">Mychaliska G, Bryner B, Dechert R, et al. Safety and efficacy of perflubron-induced lung growth in neonates with congenital diaphragmatic hernia: Results of a prospective randomized trial. J Pediatr Surg 2015; 50:1083.</a></li><li><a class="nounderline abstract_t">Cannon ML, Cheifetz IM, Craig DM, et al. Optimizing liquid ventilation as a lung protection strategy for neonatal cardiopulmonary bypass: full functional residual capacity dosing is more effective than half functional residual capacity dosing. Crit Care Med 1999; 27:1140.</a></li><li><a class="nounderline abstract_t">Hirschl RB, Parent A, Tooley R, et al. Liquid ventilation improves pulmonary function, gas exchange, and lung injury in a model of respiratory failure. Ann Surg 1995; 221:79.</a></li><li><a class="nounderline abstract_t">Cullen AB, Cox CA, Hipp SJ, et al. Intra-tracheal delivery strategy of gentamicin with partial liquid ventilation. Respir Med 1999; 93:770.</a></li><li class="breakAll">Sekins KM, Deilman GW, Shaffer TH, et al. Acoustic and physical properties of PFC liquids pertinent to ultrasound lung hyperthermia. 10th Annual North American Hyperthermia Group. Radiation Res Soc. April, 1990.</li><li><a class="nounderline abstract_t">Wolfson MR, Greenspan JS, Shaffer TH. Pulmonary administration of vasoactive substances by perfluorochemical ventilation. Pediatrics 1996; 97:449.</a></li><li><a class="nounderline abstract_t">Orizondo RA, Nelson DL, Fabiilli ML, Cook KE. Effects of Fluorosurfactant Structure and Concentration on Drug Availability and Biocompatibility in Water-in-Perfluorocarbon Emulsions for Pulmonary Drug Delivery. Colloid Polym Sci 2017; 295:2413.</a></li><li><a class="nounderline abstract_t">Dickson EW, Heard SO, Otto S, et al. Efficacy of a novel perfluorocarbon-based intrapulmonary drug delivery system. Crit Care Med 1998; 26:143A.</a></li><li><a class="nounderline abstract_t">Franz AR, Röhlke W, Franke RP, et al. Pulmonary administration of perfluorodecaline- gentamicin and perfluorodecaline- vancomycin emulsions. Am J Respir Crit Care Med 2001; 164:1595.</a></li><li><a class="nounderline abstract_t">Dembinski R, Bensberg R, Marx G, et al. Semi-fluorinated alkanes as carriers for drug targeting in acute respiratory failure. Exp Lung Res 2010; 36:499.</a></li><li><a class="nounderline abstract_t">Orizondo RA, Babcock CI, Fabiilli ML, et al. Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin. J Aerosol Med Pulm Drug Deliv 2014; 27:392.</a></li><li><a class="nounderline abstract_t">Dickson EW, Heard SO, Tarara TE, et al. Liquid ventilation with perflubron in the treatment of rats with pneumococcal pneumonia. Crit Care Med 2002; 30:393.</a></li><li><a class="nounderline abstract_t">Yoshida S, Sekine Y, Shinozuka N, et al. The efficacy of partial liquid ventilation in lung protection during hypotension and cardiac arrest: preliminary study of lung transplantation using non-heart-beating donors. J Heart Lung Transplant 2005; 24:723.</a></li><li><a class="nounderline abstract_t">Loehe F, Mueller C, Bittmann I, et al. Influence of long-term preservation with endobronchially administered perfluorodecalin on pulmonary graft function. Transplantation 2000; 70:1417.</a></li><li><a class="nounderline abstract_t">Kohlhauer M, Berdeaux A, Kerber RE, et al. Liquid Ventilation for the Induction of Ultrafast Hypothermia in Resuscitation Sciences: A Review. Ther Hypothermia Temp Manag 2016; 6:63.</a></li><li><a class="nounderline abstract_t">Greenspan JS, Wolfson MR, Rubenstein SD, Shaffer TH. Liquid ventilation of human preterm neonates. J Pediatr 1990; 117:106.</a></li><li><a class="nounderline abstract_t">Hirschl RB, Conrad S, Kaiser R, et al. Partial liquid ventilation in adult patients with ARDS: a multicenter phase I-II trial. Adult PLV Study Group. Ann Surg 1998; 228:692.</a></li><li><a class="nounderline abstract_t">Gauger PG, Pranikoff T, Schreiner RJ, et al. Initial experience with partial liquid ventilation in pediatric patients with the acute respiratory distress syndrome. Crit Care Med 1996; 24:16.</a></li><li><a class="nounderline abstract_t">Greenspan JS, Fox WW, Rubenstein SD, et al. Partial liquid ventilation in critically ill infants receiving extracorporeal life support. Philadelphia Liquid Ventilation Consortium. Pediatrics 1997; 99:E2.</a></li><li><a class="nounderline abstract_t">Croce MA, Fabian TC, Patton JH Jr, et al. Partial liquid ventilation decreases the inflammatory response in the alveolar environment of trauma patients. J Trauma 1998; 45:273.</a></li><li><a class="nounderline abstract_t">Hirschl RB, Croce M, Gore D, et al. Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 165:781.</a></li><li><a class="nounderline abstract_t">Hirschl RB, Philip WF, Glick L, et al. A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia. J Pediatr Surg 2003; 38:283.</a></li><li><a class="nounderline abstract_t">Kacmarek RM, Wiedemann HP, Lavin PT, et al. Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 173:882.</a></li><li><a class="nounderline abstract_t">Kaushal A, McDonnell CG, Davies MW. Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2013; :CD003845.</a></li><li><a class="nounderline abstract_t">Galvin IM, Steel A, Pinto R, et al. Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2013; :CD003707.</a></li><li><a class="nounderline abstract_t">Hagerty RD, Phelan MP, Morrison SC, Hatem SF. Radiographic detection of perflubron fluoromediastinum and fluororetroperitoneum 9 years after partial liquid ventilation. Emerg Radiol 2008; 15:71.</a></li><li><a class="nounderline abstract_t">Servaes S, Epelman M. Perflubron residua: 12 years following therapy. Pediatr Radiol 2009; 39:393.</a></li><li><a class="nounderline abstract_t">Tak S, Barraclough M. 'Pseudo-calcifications': detection of perfluorocarbon residue on a computed tomography scan 15 years after liquid ventilation therapy at 3 months of age. BMJ Case Rep 2018; 2018.</a></li></ol></div><div id="topicVersionRevision">Topic 1608 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8647601" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7780839" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Liquid ventilation: it's not science fiction anymore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14461129" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Of mice as fish.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5938414" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1391434" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Overview of progress in the fluorocarbon approach to in vivo oxygen delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8715647" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Liquid ventilation: a comprehensive overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3554691" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A brief review: liquid ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1437347" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Liquid ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8732549" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Physiology and clinical role of liquid ventilation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Perfluorochemical (PFC) uptake and biodistribution following liquid assisted ventilation in the immature lamb</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542545" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Structure-function of airway generations 0 to 4 in the preterm lamb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Liquid ventilation of neonates: Uptake, distribution, and elimination of the liquid</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171732" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The pulmonary and systemic distribution and elimination of perflubron from adult patients treated with partial liquid ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852261" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Liquid ventilation: new frontiers in the treatment of ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3145482" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fluorocarbon ventilation: maximal expiratory flows and CO2 elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8778584" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8725693" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Advances in the management of respiratory failure. Liquid ventilation in the setting of respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817707" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Positive end-expiratory pressure improves gas exchange and pulmonary mechanics during partial liquid ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319476" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intratracheal perfluorocarbon administration combined with mechanical ventilation in experimental respiratory distress syndrome: dose-dependent improvement of gas exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2026035" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Perfluorocarbon-associated gas exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3781984" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Respiratory distress and surfactant inhibition following vagotomy in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944026" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pulmonary vascular resistance in the fluorocarbon-filled lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8674344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Partial liquid ventilation enhances surfactant phospholipid production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8482099" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lung lavage with oxygenated perfluorochemical liquid in acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15246588" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of partial liquid ventilation on lipopolysaccharide-induced inflammatory responses in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7664556" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6087518" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of perfluorochemical blood substitutes on human neutrophil function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8946649" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Perfluorocarbon protects lung epithelial cells from neutrophil-mediated injury in an in vitro model of liquid ventilation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135729" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Perfluorohexane attenuates proinflammatory and procoagulatory response of activated monocytes and alveolar macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11546973" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Perfluorochemical liquids modulate cell-mediated inflammatory responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10781432" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Perflubron attenuates neutrophil adhesion to activated endothelial cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323898" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Perfluorocarbon reduces cell damage from blast injury by inhibiting signal paths of NF-κB, MAPK and Bcl-2/Bax signaling pathway in A549 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26935986" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effects of perfluorocarbon on ICAM-1 expression in LPS-induced A549 cells and the potential mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9059195" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Partial liquid ventilation--turning back a PAGE on evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6506339" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Physiological effects of ventilation with liquid fluorocarbon at controlled temperatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3941549" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A new approach to induced hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637815" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Advanced ventilation in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Partial liquid ventilation with LiquiVent' increases endogenous surfactant production in premature lambs with respiratory distress syndrome (RDS)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569018" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475663" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Liquid ventilation in adults, children, and full-term neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6422432" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Liquid ventilation: effects on pulmonary function in distressed meconium-stained lambs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8861466" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Partial liquid ventilation in newborn patients with congenital diaphragmatic hernia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269972" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Partial liquid ventilation and nitric oxide in congenital diaphragmatic hernia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7472977" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Combined gas ventilation and perfluorochemical tracheal instillation as an alternative treatment for lethal congenital diaphragmatic hernia in lambs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7587262" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Perfluorocarbon-associated gas exchange improves pulmonary mechanics, oxygenation, ventilation, and allows nitric oxide delivery in the hypoplastic lung congenital diaphragmatic hernia lamb model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25799085" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Safety and efficacy of perflubron-induced lung growth in neonates with congenital diaphragmatic hernia: Results of a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10397219" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Optimizing liquid ventilation as a lung protection strategy for neonatal cardiopulmonary bypass: full functional residual capacity dosing is more effective than half functional residual capacity dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7826165" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Liquid ventilation improves pulmonary function, gas exchange, and lung injury in a model of respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10603625" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intra-tracheal delivery strategy of gentamicin with partial liquid ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10603625" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intra-tracheal delivery strategy of gentamicin with partial liquid ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8632927" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pulmonary administration of vasoactive substances by perfluorochemical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30220774" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effects of Fluorosurfactant Structure and Concentration on Drug Availability and Biocompatibility in Water-in-Perfluorocarbon Emulsions for Pulmonary Drug Delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of a novel perfluorocarbon-based intrapulmonary drug delivery system</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719295" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pulmonary administration of perfluorodecaline- gentamicin and perfluorodecaline- vancomycin emulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20939753" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Semi-fluorinated alkanes as carriers for drug targeting in acute respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476046" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889317" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Liquid ventilation with perflubron in the treatment of rats with pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15949733" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The efficacy of partial liquid ventilation in lung protection during hypotension and cardiac arrest: preliminary study of lung transplantation using non-heart-beating donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118083" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Influence of long-term preservation with endobronchially administered perfluorodecalin on pulmonary graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26910322" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Liquid Ventilation for the Induction of Ultrafast Hypothermia in Resuscitation Sciences: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2115078" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Liquid ventilation of human preterm neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9833808" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Partial liquid ventilation in adult patients with ARDS: a multicenter phase I-II trial. Adult PLV Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565522" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Initial experience with partial liquid ventilation in pediatric patients with the acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096170" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Partial liquid ventilation in critically ill infants receiving extracorporeal life support. Philadelphia Liquid Ventilation Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9715184" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Partial liquid ventilation decreases the inflammatory response in the alveolar environment of trauma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897644" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12632336" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254269" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Partial liquid ventilation in adult patients with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450545" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23881653" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17972121" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Radiographic detection of perflubron fluoromediastinum and fluororetroperitoneum 9 years after partial liquid ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19189093" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Perflubron residua: 12 years following therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507033" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : 'Pseudo-calcifications': detection of perfluorocarbon residue on a computed tomography scan 15 years after liquid ventilation therapy at 3 months of age.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
